Current eye research · 2026
Difference in Ocular Perfusion Drop After Intravitreal Aflibercept in Patients with Neovascular AMD and Diabetic Macular Edema.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Karl Nina Anna Maria, Schuhmayer Anna Cornelia, Pomberger Leon, Eidherr Markus, Khalil Haidar, Kallab Martin, Rothbächer Jan, Strohmaier Clemens, Huemer Josef, Bolz Matthias, Reisinger Anna Sophie
Аннотация
PURPOSE: Vascular endothelial growth factor (VEGF) is a factor in the pathogenesis of Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME), yet they differ in pathogenesis. It has been shown that only patients with diabetic retinopathy have elevated VEGF levels in the aqueous humor. Intravitreal injections of anti-VEGF substances have been the gold standard in treating diseases for several years, but an impact on ocular perfusion has been assumed. This study aimed to investigate the effects of intravitreal aflibercept injection (IVI) on ocular perfusion in patients with AMD and DME.
METHODS: This prospective study included 36 eyes of 36 patients, with 18 patients having nAMD (n = 18) and 18 patients having DME (n = 18), all treated with IVI. Ocular perfusion was measured using Laser Speckle Flowgraphy (LSFG). The parameter Mean Blur Rate (MBR) reflects erythrocyte flow velocity and serves as an indirect marker of perfusion. MBR was measured at the optic nerve head (ONH). The device's software can analyze MBR in areas of major retinal vessels (MV) and in microperfusion areas of the tissue (MT). Measurements were conducted at three time points (before scheduled IVI, as well as 1 week and 4 weeks after).
RESULTS: In patients with AMD, significant decrease in MV was observed, while no significant change was noted for MV in patients with DME (Analysis of Variance, ANOVA, p = 0.04 vs. p = 0.2). However, both groups showed a significant decrease in MT (ANOVA, p < 0.001 for both groups).
CONCLUSION: The results indicate that retinal perfusion as measured with LSFG is less impaired in patients with DME following IVI treatment. This could be related to endothelial dysfunction, which appears to be restricted to retinal endothelial cells, as MT as a surrogate marker of choroidal perfusion showed a significant reduction in the DME group. Responses highlight physiological differences between retinal and choroidal capillaries.
METHODS: This prospective study included 36 eyes of 36 patients, with 18 patients having nAMD (n = 18) and 18 patients having DME (n = 18), all treated with IVI. Ocular perfusion was measured using Laser Speckle Flowgraphy (LSFG). The parameter Mean Blur Rate (MBR) reflects erythrocyte flow velocity and serves as an indirect marker of perfusion. MBR was measured at the optic nerve head (ONH). The device's software can analyze MBR in areas of major retinal vessels (MV) and in microperfusion areas of the tissue (MT). Measurements were conducted at three time points (before scheduled IVI, as well as 1 week and 4 weeks after).
RESULTS: In patients with AMD, significant decrease in MV was observed, while no significant change was noted for MV in patients with DME (Analysis of Variance, ANOVA, p = 0.04 vs. p = 0.2). However, both groups showed a significant decrease in MT (ANOVA, p < 0.001 for both groups).
CONCLUSION: The results indicate that retinal perfusion as measured with LSFG is less impaired in patients with DME following IVI treatment. This could be related to endothelial dysfunction, which appears to be restricted to retinal endothelial cells, as MT as a surrogate marker of choroidal perfusion showed a significant reduction in the DME group. Responses highlight physiological differences between retinal and choroidal capillaries.
Предметные рубрики MeSH
HumansReceptors, Vascular Endothelial Growth FactorProspective StudiesRecombinant Fusion ProteinsIntravitreal InjectionsFemaleMaleDiabetic RetinopathyAgedMacular EdemaLaser-Doppler FlowmetryAngiogenesis InhibitorsRegional Blood FlowRetinal VesselsBlood Flow VelocityWet Macular DegenerationVascular Endothelial Growth Factor AMiddle AgedVisual AcuityTomography, Optical CoherenceFluorescein AngiographyAged, 80 and overFollow-Up Studies